Income Statement

v3.8.0.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenue:        
Grant and licensing revenue $ 470,823 $ 220,233 $ 906,313 $ 220,233
Operating expenses:        
Research and development 1,823,922 1,693,133 5,788,755 7,127,466
General and administrative 1,188,476 820,574 4,298,072 2,935,030
Total operating expenses 3,012,398 2,513,707 10,086,827 10,062,496
Loss from operations (2,541,575) (2,293,474) (9,180,514) (9,842,263)
Interest income 5,629 5,445 17,316 24,400
Other income, net 31,768 734,509 109,211 757,044
Interest expense (110,468) (370,422)
Total non-operating income, net 37,397 629,486 126,527 411,022
Net loss (2,504,178) (1,663,988) (9,053,987) (9,431,241)
Net loss - non-controlling interest (203,371) (47,042) (344,328) (329,471)
Net loss attributable to Heat Biologics, Inc. $ (2,300,807) $ (1,616,946) $ (8,709,659) $ (9,101,770)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.06) $ (0.08) $ (0.27) $ (0.59)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted 35,786,606 19,420,026 32,695,360 15,371,267
Other comprehensive loss:        
Net loss $ (2,504,178) $ (1,663,988) $ (9,053,987) $ (9,431,241)
Unrealized loss on foreign currency translation (24,707) (36,387) (100,742) (62,961)
Total other comprehensive loss (2,528,885) (1,700,375) (9,154,729) (9,494,202)
Comprehensive loss attributable to non-controlling interest (203,371) (47,042) (344,328) (329,471)
Comprehensive loss $ (2,325,514) $ (1,653,333) $ (8,810,401) $ (9,164,731)

Source